Chronic Lymphocytic Leukemia | Specialty

Dr. John Byrd on Challenges in CLL

June 21st 2016

Ibrutinib Highly Effective for Del17p CLL in Combined Analysis

June 11th 2016

Ibrutinib continued to demonstrate impressive antitumor activity in a pooled analysis of 243 patients with deletion 17p chronic lymphocytic leukemia.

Efforts Continue to Optimize Ibrutinib in CLL

June 2nd 2016

Jennifer Brown, MD, discusses the findings and impact of the RESONATE and RESONATE-2 trials, as well as the role of ibrutinib in older and younger patients with chronic lymphocytic leukemia in both the frontline and relapsed settings.

Expert Sheds Light on Role of Next-Generation Agents in CLL

June 1st 2016

Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.

Frontline Ibrutinib Approved in Europe for CLL

June 1st 2016

The European Commission has approved ibrutinib (Imbruvica) as a first-line treatment for patients with chronic lymphocytic leukemia.

Dr. Wierda on Immunotherapy Agents for Patients With CLL

May 31st 2016

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).

FDA Updates Ibrutinib CLL Label With New OS, Combo Data

May 9th 2016

The FDA has expanded the label of ibrutinib (Imbruvica) to include overall survival results in treatment-naive patients with chronic lymphocytic leukemia, as well as outcomes with the BTK inhibitor when combined with bendamustine and rituximab in relapsed/refractory patients with CLL.

CHMP Recommends Frontline Approval for Ibrutinib in CLL

April 29th 2016

The Committee for Medicinal Products for Human Use has recommended the frontline approval for ibrutinib (Imbruvica) as a single-agent for patients with chronic lymphocytic leukemia.

Acalabrutinib Challenges Ibrutinib in High-Risk CLL Trial

April 22nd 2016

Patients with relapsed chronic lymphocytic leukemia face a difficult treatment journey, but a phase III safety and efficacy trial involving the second-generation Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) will help inform oncologists about whether the emerging agent can offer a greater benefit to patients with high-risk disease over ibrutinib (Imbruvica).

FDA Approves Venetoclax for CLL

April 11th 2016

The FDA approved the BCL-2 inhibitor venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) who have a 17p deletion (del[17p]), following at least 1 prior therapy.

Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL

April 4th 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).

Optimizing Current Treatments for CLL as New Agents Are Investigated

April 2nd 2016

Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.

Byrd Says Frontline Ibrutinib Approval Moves CLL Closer to a Cure

March 24th 2016

John Byrd, MD, explains why he believes the ibrutinib approval is practice changing, and how he thinks the agent should be utilized next.

Dr. Stilgenbauer on Activity With Venetoclax in Patients With CLL

March 22nd 2016

Stephen Stilgenbauer, MD, associate professor, Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of Ulm, Germany, discusses the clinical activity seen with venetoclax in patients with chronic lymphocytic leukemia, according to results of the open-label, single-arm, multicenter M13-982 study.

Dr. Byrd on Ibrutinib's Impact on Treatment Landscape in CLL

March 21st 2016

John Byrd, MD, director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, discusses the RESONATE 2 study, which looked at ibrutinib versus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL).

Newer Agents, Combinations Being Studied for Targeted Therapies in CLL

March 20th 2016

Targeted agents, particularly ibrutinib and idelalisib, are becoming increasingly important in the treatment of chronic lymphocytic leukemia, and have replaced chemotherapy in many settings.

Dr. Susan O'Brien on Next-Generation Small Molecules in CLL

March 20th 2016

Susan O’Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).

Extended Phase III Data Illuminates Ibrutinib Survival Benefit in CLL

March 20th 2016

Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.

Dr. Jennifer Brown on RESONATE 2 Trial in CLL

March 19th 2016

Jennifer Brown MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses RESONATE 2 and frontline ibrutinib use in patients with chronic lymphocytic leukemia (CLL).

Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL

March 19th 2016

A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.